Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Ralph GruppoMaria-Fernanda López-FernándezTung T WynnWerner EnglMarlies SharkhawySrilatha TangadaPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)
Rurioctocog alfa pegol was well tolerated and effective for perioperative use in patients with haemophilia A and showed no signs of immunogenicity.